Roivant Sciences (ROIV)
Market Price (12/24/2025): $22.45 | Market Cap: $15.3 BilSector: Health Care | Industry: Biotechnology
Roivant Sciences (ROIV)
Market Price (12/24/2025): $22.45Market Cap: $15.3 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -28% | Trading close to highsDist 52W High is -2.1%, Dist 3Y High is -2.1% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -1.2 Bil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5659% |
| Low stock price volatilityVol 12M is 33% | Expensive valuation multiplesP/SPrice/Sales ratio is 752x | |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -45%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -24%, Rev Chg QQuarterly Revenue Change % is -65% | |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 1629% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3787%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3858% | ||
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 128% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.6% | ||
| Key risksROIV key risks include [1] its high-burn, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -28% |
| Low stock price volatilityVol 12M is 33% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Trading close to highsDist 52W High is -2.1%, Dist 3Y High is -2.1% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -1.2 Bil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5659% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 752x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -45%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -24%, Rev Chg QQuarterly Revenue Change % is -65% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 1629% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3787%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3858% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 128% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.6% |
| Key risksROIV key risks include [1] its high-burn, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
1. Positive Phase 3 Clinical Trial Results for BrepocitinibRoivant Sciences, through its subsidiary Priovant Therapeutics, announced positive results from a late-stage clinical study in September 2025 for brepocitinib in treating dermatomyositis, an autoimmune disease. Patients receiving the drug showed statistically significant improvement on the primary and all nine key secondary endpoints. Roivant, which owns 75% of Priovant, anticipates filing for U.S. Food and Drug Administration (FDA) approval for brepocitinib in the first half of 2026, with the drug holding potential to become a blockbuster for rare autoimmune diseases.
2. Strong Financial Position and Shareholder Return Initiatives
Roivant maintained a robust financial standing, reporting consolidated cash, cash equivalents, restricted cash, and marketable securities of approximately $4.5 billion as of June 30, 2025, and $4.4 billion as of September 30, 2025, with no debt on its balance sheet. The company also completed a $1.5 billion share repurchase program by June 2025, reducing outstanding shares by over 15%, and subsequently approved a new $500 million share repurchase program, demonstrating a commitment to returning value to shareholders.
3. Advancements Across a Robust Late-Stage Pipeline
Beyond brepocitinib, Roivant highlighted significant progress in its other late-stage pipeline assets. In June 2025, potentially registrational studies for IMVT-1402 were initiated in Graves' disease and Sjögren's disease. Immunovant, a Roivant-led company, also released encouraging Graves' disease remission data and secured approximately $550 million in financing, extending its cash runway. Positive results for batoclimab in Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) studies were also announced in March 2025.
4. Numerous Analyst Upgrades and Increased Price Targets
Analyst sentiment towards Roivant Sciences turned increasingly positive during the period, with several firms raising their price targets and the consensus rating shifting to "Moderate Buy." For instance, Leerink Partners increased its price target to $18 in August 2025 and later to $32, Goldman Sachs raised its target to $24 and subsequently to $33, H.C. Wainwright to $26, and Guggenheim to $25.
5. Positive Outlook from 2025 Investor Day and Strategic Vision
Roivant's Investor Day on December 11, 2025, provided a strong forward-looking perspective, outlining plans for more than three product launches, four NDA/BLA filings, eight pivotal study readouts, and three proof-of-concept study readouts over the next three years. This strategic vision for long-term growth and commercialization of its pipeline assets further bolstered investor confidence. Show more
Stock Movement Drivers
Fundamental Drivers
The 52.3% change in ROIV stock from 9/23/2025 to 12/23/2025 was primarily driven by a 74.2% change in the company's P/S Multiple.| 9232025 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 14.74 | 22.45 | 52.31% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 23.23 | 20.33 | -12.50% |
| P/S Multiple | 431.60 | 751.99 | 74.23% |
| Shares Outstanding (Mil) | 680.29 | 680.95 | -0.10% |
| Cumulative Contribution | 52.31% |
Market Drivers
9/23/2025 to 12/23/2025| Return | Correlation | |
|---|---|---|
| ROIV | 52.3% | |
| Market (SPY) | 3.7% | 13.5% |
| Sector (XLV) | 13.2% | 23.4% |
Fundamental Drivers
The 94.5% change in ROIV stock from 6/24/2025 to 12/23/2025 was primarily driven by a 167.5% change in the company's P/S Multiple.| 6242025 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 11.54 | 22.45 | 94.54% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 29.05 | 20.33 | -30.03% |
| P/S Multiple | 281.07 | 751.99 | 167.54% |
| Shares Outstanding (Mil) | 707.63 | 680.95 | 3.77% |
| Cumulative Contribution | 94.26% |
Market Drivers
6/24/2025 to 12/23/2025| Return | Correlation | |
|---|---|---|
| ROIV | 94.5% | |
| Market (SPY) | 13.7% | 16.9% |
| Sector (XLV) | 16.4% | 27.7% |
Fundamental Drivers
The 87.6% change in ROIV stock from 12/23/2024 to 12/23/2025 was primarily driven by a 216.5% change in the company's P/S Multiple.| 12232024 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 11.97 | 22.45 | 87.55% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 37.05 | 20.33 | -45.13% |
| P/S Multiple | 237.63 | 751.99 | 216.45% |
| Shares Outstanding (Mil) | 735.47 | 680.95 | 7.41% |
| Cumulative Contribution | 86.52% |
Market Drivers
12/23/2024 to 12/23/2025| Return | Correlation | |
|---|---|---|
| ROIV | 87.6% | |
| Market (SPY) | 16.7% | 43.9% |
| Sector (XLV) | 13.2% | 42.7% |
Fundamental Drivers
The 220.3% change in ROIV stock from 12/24/2022 to 12/23/2025 was primarily driven by a 672.7% change in the company's P/S Multiple.| 12242022 | 12232025 | Change | |
|---|---|---|---|
| Stock Price ($) | 7.01 | 22.45 | 220.26% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 50.42 | 20.33 | -59.68% |
| P/S Multiple | 97.31 | 751.99 | 672.74% |
| Shares Outstanding (Mil) | 699.89 | 680.95 | 2.71% |
| Cumulative Contribution | 220.02% |
Market Drivers
12/24/2023 to 12/23/2025| Return | Correlation | |
|---|---|---|
| ROIV | 106.2% | |
| Market (SPY) | 48.4% | 41.7% |
| Sector (XLV) | 18.2% | 38.7% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ROIV Return | � | -1% | -21% | 41% | 5% | 92% | � |
| Peers Return | � | -36% | -8% | 77% | 192% | 86% | � |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 114% |
Monthly Win Rates [3] | |||||||
| ROIV Win Rate | � | 50% | 33% | 67% | 58% | 67% | |
| Peers Win Rate | 56% | 43% | 47% | 57% | 45% | 58% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| ROIV Max Drawdown | � | -42% | -72% | -13% | -12% | -23% | |
| Peers Max Drawdown | � | -51% | -48% | -47% | -28% | -16% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: BBIO, INSM, ARQT, APLS, SMMT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/23/2025 (YTD)
How Low Can It Go
| Event | ROIV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -79.2% | -25.4% |
| % Gain to Breakeven | 381.1% | 34.1% |
| Time to Breakeven | 1,217 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -4.8% | -33.9% |
| % Gain to Breakeven | 5.1% | 51.3% |
| Time to Breakeven | 34 days | 148 days |
Compare to VRTX, ALPS, EVMN, MPLT, TTRX
In The Past
Roivant Sciences's stock fell -79.2% during the 2022 Inflation Shock from a high on 12/20/2021. A -79.2% loss requires a 381.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Roivant Sciences:
Alphabet for biotech companies: Similar to how Alphabet oversees various "Other Bets" (like Waymo or Verily) as semi-independent entities, Roivant creates and manages multiple "vants" (subsidiary companies) each focused on developing specific drug candidates.
IAC (InterActiveCorp) for drug development startups: Like IAC, which is known for building and spinning off numerous internet and media companies (such as Match Group or Vimeo), Roivant builds specialized biotech startups around individual drug assets, often with the goal of later public listing or sale.
AI Analysis | Feedback
- VTAMA (tapinarof) cream: A topical medication approved for the treatment of plaque psoriasis in adults, and currently being investigated for atopic dermatitis.
AI Analysis | Feedback
Roivant Sciences (ROIV) is a unique biopharmaceutical company that operates through a "vant" model, creating and developing numerous subsidiary companies (known as "vants") focused on specific drug candidates or therapeutic areas. Its primary business involves discovering, developing, and commercializing new medicines, often through these standalone entities.
Given this business model, Roivant Sciences does not sell primarily to individuals. Instead, its major "customers" or strategic partners are other pharmaceutical companies and healthcare entities that acquire its subsidiaries, license its drug candidates, or enter into significant collaboration agreements. These transactions represent Roivant's primary revenue drivers from other companies.
Based on its strategic transactions and partnerships, Roivant's major customers/partners include:
- Sumitomo Pharma Co., Ltd. (TYO: 4506): Acquired Myovant Sciences, one of Roivant's most prominent "vants," which developed and commercialized products like Orgovyx and Myfembree. This acquisition represented a significant transaction and revenue source for Roivant.
- Pfizer Inc. (NYSE: PFE): Roivant and Pfizer entered into a collaboration agreement for the development and commercialization of an oral PDE4 inhibitor (now known as RVVT-1358) for dermatological conditions. Pfizer made significant upfront payments and an equity investment in Roivant as part of this partnership. Pfizer also acquired certain legacy assets from Roivant.
- Other pharmaceutical companies and institutional investors that participate in various licensing deals, partnerships, or equity investments in Roivant's "vants" or the parent company itself, though these may vary over time and might not be consistently disclosed as "customers" in the traditional sense.
AI Analysis | Feedback
nullAI Analysis | Feedback
Matt Gline, Chief Executive Officer
Matt Gline joined Roivant in March 2016 and assumed the role of Chief Executive Officer in January 2021, having previously served as Chief Financial Officer. Prior to joining Roivant, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, focusing on technology and data strategy from April 2014 to March 2016. He co-founded Fourthree, a risk analytics technology and consulting company, and also served as a Vice President at Barclays, Enterprise Risk Management Advisory, from 2008 to 2012. Mr. Gline earned his A.B. in Physics from Harvard College and knew Roivant's founder, Vivek Ramaswamy, from their time at Harvard.
Richard Pulik, Chief Financial Officer
Richard Pulik has served as Chief Financial Officer of Roivant Sciences since September 2021. He brings over twenty years of industry experience, including his previous role as the Global Head of Business Development & Licensing and Portfolio Management, Oncology at Novartis, where he was also a member of Novartis's Innovation Management Board and the Novartis Oncology Leadership Team. Mr. Pulik joined Novartis in 2012 as a Senior Director, Mergers & Acquisitions in Basel, Switzerland. Earlier in his career, he gained experience in investment banking and mergers & acquisitions at Bank of America/Merrill Lynch and UBS Investment Bank, holding a background in finance and economics from The Wharton School and University of Pennsylvania.
Vivek Ramaswamy, Founder
Vivek Ramaswamy founded Roivant Sciences in 2014, with a vision to apply technology to drug development and build subsidiary life sciences companies. He served as CEO until 2021 and stepped down from the company's board of directors in February 2023 to focus on his U.S. presidential campaign. Ramaswamy's business model involved acquiring and developing overlooked pharmaceuticals. He co-founded StudentBusinesses.com, which was acquired in 2009. He also worked at the hedge fund QVT Financial from 2007 to 2014. In 2020, a pivotal moment for Roivant and Ramaswamy's wealth came when Sumitomo Dainippon purchased a portfolio of five Roivant drugs and a 10% company stake for $3 billion. In 2022, he co-founded the investment firm Strive Asset Management.
Mayukh Sukhatme, MD, President and Chief Investment Officer
Mayukh Sukhatme is President and Chief Investment Officer of Roivant, and also serves on its Board of Directors. He joined Roivant in 2015 and is responsible for identifying, performing diligence on, devising development strategies for, and transacting on new therapeutic programs. Dr. Sukhatme also helps guide Roivant's capital allocation decisions across its biopharmaceutical subsidiary companies, having previously served as President of Roivant Pharma and Chief Business Officer.
Frank Torti, MD, Vant Chair
Frank Torti is the Vant Chair at Roivant Sciences. In this role, Dr. Torti serves as Chairman, Executive Chairman, or CEO of the public and private biopharmaceutical companies (Vants) at Roivant, overseeing their businesses. He joined Roivant in 2018 from New Enterprise Associates (NEA), one of the largest venture capital firms globally, where he was a partner. Dr. Torti was the founding CEO and Chairman of Telavant from its inception until its sale to Roche for $7.25 billion. Throughout his career, he has been involved in over $22 billion in capital formation through fundraising, partnerships, and corporate acquisitions, and has seen companies he was involved with complete approximately twenty initial public offerings and M&A transactions.
AI Analysis | Feedback
Key Risks to Roivant Sciences (ROIV)
Roivant Sciences (ROIV), a biopharmaceutical company, faces several significant risks inherent to its business model, primarily revolving around the unpredictable nature of drug development and commercialization, its financial sustainability, and intense market competition.
- Clinical Development and Regulatory Risks: Roivant Sciences' business model is heavily reliant on the successful development and regulatory approval of its drug candidates. The biopharmaceutical industry is highly regulated, and drug development is an inherently risky, costly, and lengthy process with uncertain outcomes. Delays, failures in clinical trials, or an inability to obtain necessary regulatory approvals could severely hinder the company's ability to bring new products to market, leading to significant financial losses and impacting its future viability. The company's valuation is largely a bet on the future regulatory success of its pipeline assets.
- Financial Sustainability and Path to Profitability: Roivant Sciences is characterized as a "high-burn, pipeline-dependent biopharma company" that consistently reports significant operating losses. Although the company has a substantial cash position, partly due to past asset sales, it continues to incur considerable cash burn due to high research and development (R&D) expenses, which are integral to its business model. Roivant has not generated substantial revenue from its core operations, with its revenue streams being volatile and primarily driven by strategic asset sales and collaboration milestones rather than consistent product sales. This aggressive investment in its pipeline poses challenges to achieving sustained profitability.
- Intense Competition: Roivant Sciences operates within a highly competitive biopharmaceutical industry. The company faces stiff competition from numerous players, including large, established pharmaceutical companies such as Pfizer, Novartis, and Johnson & Johnson, as well as other biotechnology firms like Biogen, Amgen, and Regeneron Pharmaceuticals. Additionally, emerging biotech firms and technology-driven startups leveraging AI and machine learning for drug discovery also contribute to the competitive landscape. This intense competition can impact Roivant's ability to gain market share, secure partnerships, and achieve commercial success for its products.
AI Analysis | Feedback
The emergence and advanced clinical development of competing TL1A inhibitors poses a significant emerging threat to Roivant Sciences. Roivant's key asset, RVT-3101 (partnered with Pfizer), is a TL1A antibody targeting inflammatory bowel diseases (IBD). Several other companies are developing competing TL1A inhibitors, most notably Merck with PRA023 (acquired through Prometheus Biosciences), which is also in late-stage clinical trials for IBD. The success of these competing TL1A inhibitors, potentially demonstrating superior efficacy, safety, or delivery profiles, or achieving faster market entry, could directly erode the market share and commercial potential of RVT-3101, which is a cornerstone of Roivant's near-term value proposition.
AI Analysis | Feedback
Roivant Sciences (ROIV) is a clinical-stage biopharmaceutical company with a pipeline of investigational drugs. While the company does not currently have its own approved products generating significant sales, it is developing therapies for various conditions. Below are the addressable market sizes for the diseases targeted by Roivant's main pipeline products:
- IMVT-1402 (Immunovant):
- Graves' Disease: The global market size was valued at approximately USD 403.48 million in 2024 and is projected to reach USD 582.64 million by 2032. North America dominates the global market. Other estimates for the global market include USD 430.6 million in 2025, expected to reach USD 606.4 million by 2032, and USD 641.22 million in 2024, projected to reach USD 1.01 billion by 2032.
- Myasthenia Gravis: The global myasthenia gravis treatment market size was USD 1.40 billion in 2023 and is projected to grow to USD 2.75 billion by 2032. North America held a 49.29% share of the global market in 2023. The market across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is projected to grow from $6.1 billion in 2024 to $10.5 billion in 2034.
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): The global CIDP treatment market size was valued at USD 1.2 billion in 2023 and is projected to reach USD 2.5 billion by 2032. Another source indicates the global market was valued at USD 1.87 billion in 2024 and is expected to reach USD 3.33 billion by 2032. North America was the largest region in the CIDP market in 2024.
- Difficult-to-Treat Rheumatoid Arthritis: null
- Sjögren's Disease: The global Sjögren's syndrome market was valued at USD 168.8 million in 2023 and is expected to reach USD 226.0 million by 2034. Other estimates for the global market include US$201.70 million in 2023, expected to reach US$277.82 million by 2033, and USD 234.6 million in 2022, expected to reach USD 308.4 million in 2030. The U.S. Sjögren's Syndrome Market is estimated to be valued at USD 64.8 billion in 2025 and is anticipated to reach USD 83.4 billion by 2035.
- Cutaneous Lupus Erythematosus (CLE): The global cutaneous lupus erythematosus market size was valued at USD 2.93 billion in 2024 and is projected to reach USD 7.90 billion by 2032. Another report indicates the global market size was USD 227.2 million in 2023, expected to reach USD 373.7 million by 2034. The 7 major markets (US, EU4, UK, and Japan) reached a value of USD 237.8 million in 2024 and are expected to reach USD 385.5 million by 2035. North America dominates the market.
- Thyroid Eye Disease (TED): The global Thyroid Eye Disease market size was valued at USD 2.15 billion in 2024 and is projected to reach USD 2.97 billion by 2029. Other estimates for the global market include USD 2.26 billion in 2024, predicted to reach USD 4.02 billion by 2034, and USD 4.94 billion in 2025, projected to reach USD 7.55 billion by 2030. North America was the largest region in the TED market in 2024.
- Batoclimab (Immunovant):
- Myasthenia Gravis: (See above under IMVT-1402)
- Graves' Disease: (See above under IMVT-1402)
- Brepocitinib (Priovant):
- Dermatomyositis: The global dermatomyositis market size was valued at USD 573.4 million in 2024 and is estimated to reach USD 931.57 million by 2033. Other estimates for the global market include approximately USD 1.2 billion in 2023, projected to reach USD 2.3 billion by 2032. The 7 major markets (US, EU4, UK, and Japan) reached a value of USD 199.4 million in 2024 and are expected to reach USD 290.0 million by 2035.
- Non-Infectious Uveitis: The global non-infectious uveitis market was valued at USD 1.8 billion in 2024 and is projected to reach USD 3.2 billion by 2034. Another source indicates the global market size was USD 2.15 billion in 2024 and is projected to reach USD 4.59 billion by 2032. North America holds the largest market share, accounting for 42.1% of the global market in 2024.
- Cutaneous Sarcoidosis: Market size for cutaneous sarcoidosis specifically was not found. However, non-infectious uveitis can be associated with sarcoidosis.
- Mosliciguat (Pulmovant):
- Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD): The PH-ILD market across the top 7 markets (US, EU4, UK, and Japan) reached a value of USD 1.14 billion in 2024 and is expected to reach USD 1.74 billion by 2035. Another report indicates the PH-ILD market was valued at around USD 3 billion in 2024 and is expected to expand through 2034.
AI Analysis | Feedback
Roivant Sciences (ROIV) is anticipated to drive future revenue growth over the next two to three years primarily through the advancement and commercialization of its diverse pipeline of drug candidates. These key drivers include:
-
Launch and Commercialization of Brepocitinib: Roivant expects to file a New Drug Application (NDA) for brepocitinib in the first half of 2026, particularly for indications such as dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis. Analysts project significant sales for brepocitinib across these indications by 2035.
-
Advancement and Potential Approval of Batoclimab/IMVT-1402: This drug candidate is in development for several IgG-mediated autoimmune conditions, with results for batoclimab in Thyroid Eye Disease (TED) anticipated in the first half of 2026. This product is also expected to be a substantial revenue contributor in the future.
-
Progress and Potential Commercialization of Mosliciguat: Mosliciguat, an inhaled sGC activator for pulmonary hypertension associated with interstitial lung disease (PH-ILD), is another key pipeline asset. Topline results from its Phase 2 study are expected in the second half of 2026, paving the way for further development and potential market entry. Analysts foresee considerable sales potential for mosliciguat in PH-ILD.
-
Strategic Development through "Vants": Roivant's operational model involves creating nimble subsidiaries, or "Vants," to develop and commercialize medicines and technologies. This strategy facilitates the efficient progression of multiple drug candidates and broader pipeline expansion, ensuring a continuous stream of potential new product launches that will contribute to long-term revenue.
AI Analysis | Feedback
Share Repurchases
- Roivant Sciences completed a $1.5 billion share repurchase program in June 2025.
- An additional $500 million share repurchase program was approved by the board of directors in June 2025.
- The $1.5 billion program included the repurchase of 71,251,083 shares from Sumitomo for approximately $648.4 million, contributing to a reduction of outstanding shares by over 15% from March 31, 2024.
Share Issuance
- In September 2023, Roivant offered 19,600,685 common shares, resulting in estimated net proceeds of approximately $200.1 million.
- A February 2022 prospectus supplement noted the potential offer and sale by securityholders of up to 595,134,445 common shares, including 22,000,000 common shares issued in PIPE Financing.
- Common shares outstanding were 695,491,615 as of November 3, 2025, reflecting changes from various capital allocation activities.
Inbound Investments
- In the final quarter of 2023, Roivant Sciences sold its stake in Telavant to Roche in a deal valued at $5.3 billion (mentioned as $7.1 billion in another source), providing a significant capital influx to the company.
Outbound Investments
- Roivant Sciences has made 9 investments across sectors such as Genomics, Healthcare IT, and Infectious Diseases, with notable investments in companies like Immunovant, Datavant, and Arbutus Bio.
- The company's most recent investment was a Series A round in Lokavant on December 7, 2022.
- Annual long-term investments were $290 million in 2021, $326 million in 2022, $304 million in 2023, $248 million in 2024, and $303 million in 2025.
Capital Expenditures
- Investment in biopharmaceutical product development entails substantial upfront capital expenditures and significant risk.
- Research and development (R&D) expenses increased to $152.9 million for the three months ended June 30, 2025, compared to $120.5 million for the same period in 2024.
- For the quarter ended September 30, 2025, operating expenses, primarily driven by R&D ($164.568 million) and general and administrative expenses ($143.125 million), totaled $307.8 million. The primary focus of these expenditures is advancing Roivant's pipeline of potentially groundbreaking therapies.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ROIV. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 20.9% | 20.9% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 13.5% | 13.5% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 1.6% | 1.6% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.8% | 11.8% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Roivant Sciences
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 27.06 |
| Mkt Cap | 14.1 |
| Rev LTM | 336 |
| Op Inc LTM | -765 |
| FCF LTM | -434 |
| FCF 3Y Avg | -386 |
| CFO LTM | -427 |
| CFO 3Y Avg | -383 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 42.1% |
| Rev Chg 3Y Avg | 115.2% |
| Rev Chg Q | 121.7% |
| QoQ Delta Rev Chg LTM | 20.7% |
| Op Mgn LTM | -168.2% |
| Op Mgn 3Y Avg | -222.0% |
| QoQ Delta Op Mgn LTM | 20.6% |
| CFO/Rev LTM | -165.3% |
| CFO/Rev 3Y Avg | -221.7% |
| FCF/Rev LTM | -168.9% |
| FCF/Rev 3Y Avg | -223.7% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Discovery, development and commercialization of medicines and technologies | 33 | |||
| Single Segment | 61 | 55 | 24 | |
| Total | 33 | 61 | 55 | 24 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Discovery, development and commercialization of medicines and technologies | 4,231 | |||
| Total | 4,231 |
Price Behavior
| Market Price | $22.45 | |
| Market Cap ($ Bil) | 15.3 | |
| First Trading Date | 12/08/2020 | |
| Distance from 52W High | -2.1% | |
| 50 Days | 200 Days | |
| DMA Price | $20.16 | $13.88 |
| DMA Trend | up | up |
| Distance from DMA | 11.3% | 61.7% |
| 3M | 1YR | |
| Volatility | 31.1% | 33.3% |
| Downside Capture | -50.98 | 53.56 |
| Upside Capture | 158.58 | 107.52 |
| Correlation (SPY) | 15.7% | 44.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.54 | 0.46 | 0.34 | 0.55 | 0.78 | 0.84 |
| Up Beta | 0.99 | 0.80 | 0.87 | 0.67 | 0.83 | 0.64 |
| Down Beta | 0.51 | 0.41 | 0.67 | 0.15 | 0.62 | 0.70 |
| Up Capture | 92% | 169% | 178% | 160% | 110% | 178% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 11 | 29 | 40 | 72 | 130 | 385 |
| Down Capture | 16% | -56% | -152% | -18% | 76% | 97% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 9 | 13 | 23 | 53 | 117 | 353 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of ROIV With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| ROIV | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 92.0% | 14.9% | 18.8% | 72.9% | 9.0% | 3.7% | -11.4% |
| Annualized Volatility | 33.3% | 17.3% | 19.5% | 19.2% | 15.3% | 17.2% | 35.0% |
| Sharpe Ratio | 2.00 | 0.64 | 0.76 | 2.72 | 0.36 | 0.05 | -0.14 |
| Correlation With Other Assets | 43.1% | 43.9% | 8.5% | 5.1% | 40.5% | 26.3% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of ROIV With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| ROIV | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 17.5% | 8.4% | 14.8% | 18.9% | 11.8% | 4.7% | 35.5% |
| Annualized Volatility | 56.7% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.9% |
| Sharpe Ratio | 0.50 | 0.40 | 0.70 | 0.98 | 0.51 | 0.16 | 0.62 |
| Correlation With Other Assets | 22.7% | 25.4% | 5.5% | 2.8% | 21.5% | 11.6% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of ROIV With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| ROIV | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 16.6% | 9.9% | 14.8% | 15.1% | 6.8% | 5.4% | 69.1% |
| Annualized Volatility | 56.6% | 16.6% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.49 | 0.49 | 0.71 | 0.85 | 0.31 | 0.23 | 0.90 |
| Correlation With Other Assets | 22.7% | 25.4% | 5.7% | 2.8% | 21.5% | 11.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/10/2025 | 2.7% | -1.6% | -1.8% |
| 8/11/2025 | -2.8% | 3.1% | 17.3% |
| 5/29/2025 | 6.4% | 5.6% | 7.3% |
| 2/10/2025 | -0.9% | -3.0% | -3.1% |
| 11/12/2024 | -1.4% | -5.5% | 2.5% |
| 8/8/2024 | 6.7% | 12.4% | 20.9% |
| 5/30/2024 | -3.2% | 1.4% | -1.5% |
| 2/13/2024 | -0.6% | 6.2% | -2.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 9 | 8 |
| # Negative | 9 | 7 | 8 |
| Median Positive | 6.4% | 5.6% | 17.4% |
| Median Negative | -2.7% | -5.5% | -4.4% |
| Max Positive | 11.3% | 21.6% | 27.7% |
| Max Negative | -11.2% | -15.3% | -39.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11102025 | 10-Q 9/30/2025 |
| 6302025 | 8112025 | 10-Q 6/30/2025 |
| 3312025 | 5292025 | 10-K 3/31/2025 |
| 12312024 | 2102025 | 10-Q 12/31/2024 |
| 9302024 | 11122024 | 10-Q 9/30/2024 |
| 6302024 | 8092024 | 10-Q 6/30/2024 |
| 3312024 | 5302024 | 10-K 3/31/2024 |
| 12312023 | 2132024 | 10-Q 12/31/2023 |
| 9302023 | 11132023 | 10-Q 9/30/2023 |
| 6302023 | 8142023 | 10-Q 6/30/2023 |
| 3312023 | 6282023 | 10-K 3/31/2023 |
| 12312022 | 2132023 | 10-Q 12/31/2022 |
| 9302022 | 11142022 | 10-Q 9/30/2022 |
| 6302022 | 8152022 | 10-Q 6/30/2022 |
| 3312022 | 6282022 | 10-K 3/31/2022 |
| 12312021 | 2142022 | 10-Q 12/31/2021 |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.